Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$22.40 USD

22.40
1,189,759

-0.15 (-0.67%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Exelixis (EXEL) Up 10.6% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nalak Das headshot

Top 5 High-Flying Mid-Cap Stocks Despite a Volatile August

by Nalak Das

We have narrowed our search to five mid-cap stocks that have provided double-digit returns in the past month. These are: FN, FRSH, HRB, EXEL, PSN.

Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive

by Zacks Equity Research

Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.

Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint

by Zacks Equity Research

Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.

EXEL or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Here's Why Exelixis (EXEL) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Surging Earnings Estimates Signal Upside for Exelixis (EXEL) Stock

by Zacks Equity Research

Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth

by Zacks Equity Research

Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.

Exelixis (EXEL) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 40.91% and 4.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More

by Ahan Chakraborty

Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

EXEL or RGEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. RGEN: Which Stock Is the Better Value Option?

Exelixis (EXEL) Reports Next Week: What You Should Expect

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Exelixis (EXEL) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of -30.43% and 4.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More

by Kinjel Shah

Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.

GSK (GSK) Tops Q1 Earnings Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?